Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Ben Tran,Lisa G. Horvath,Matthew Rettig,Karim Fizazi,Martijn P. Lolkema,Tanya B. Dorff,Richard Greil,Jean-Pascal Machiels,Karen A. Autio,Sylvie Rottey,Nabil Adra,Rohan Garje,Felicia Roncolato,Scott T. Tagawa,Shahrokh F. Shariat,Mark Salvati,Shirley Poon,Hosein Kouros-Mehr

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

2020

Ben Tran
Lisa G. Horvath
Matthew Rettig
Karim Fizazi
Martijn P. Lolkema
Tanya B. Dorff
Richard Greil
Jean-Pascal Machiels
Karen A. Autio
Sylvie Rottey
Nabil Adra
Rohan Garje
Felicia Roncolato
Scott T. Tagawa
Shahrokh F. Shariat
Mark Salvati
Shirley Poon
Hosein Kouros-Mehr

TPS5590Background: Prostate-specific membrane antigen (PSMA) is a clinically validated therapeutic target for the imaging and treatment of mCRPC. AMG 160 is an HLE BiTE immune therapy designed to r...

Keywords:

T cell
Medicine
castration resistant
Half-life
in patient
Glutamate carboxypeptidase II
phase i study
Cancer research
immune therapy
Prostate cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations